melanotan i

approved as Scenesse for one rare skin condition. used off-label for tanning. long-term safety, unknown.

tier C · skin · FDA '19 Scenesse · EPP

verdict

Scenesse for erythropoietic protoporphyria (EPP). selective MC1R agonist with a real orphan-drug label. off-label cosmetic use is a different protocol on the same molecule.

if you're asking about Scenesse for EPP — decisively yes. the orphan-drug evidence is rigorous. Scenesse changed lives for patients living in functional darkness. the approved protocol is a 16 mg controlled-release implant placed by a dermatologist every two months (~$49,000 per implant). that protocol is not what gray-market injectable MT-I delivers.

if you're asking about MT-I vs MT-II for cosmetic tanning — MT-I is MC1R-selective, so the side-effect profile reported is cleaner than MT-II: less nausea, no sexual-arousal effect, milder flushing. the tanning works over 2-6 weeks. long-term safety data on cycling in healthy users does not exist for either molecule, and dermatology case literature documents new mole formation and existing nevus changes.

if you came in via the vitiligo angle — CUV105 phase 3 in vitiligo (Scenesse + NB-UVB phototherapy) finished enrollment May 2025; topline expected H2 2026. if positive, Scenesse becomes a real vitiligo drug, not just an EPP orphan. that result is the inflection point for what MT-I means as a clinical compound.

based on published evidence and disclosed clinical practice. not medical advice. dose and protocol conversations belong with a clinician.

why C-tier

C-tier because the split between validated use and community use is unusually wide. The drug has real FDA approval for a narrow rare-disease indication with rigorous trial evidence. The grey-market cosmetic tanning use is a completely different use case with no long-term safety studies, concerning dermatological observations around nevus progression, and self-injection protocols far removed from the controlled implant administration the drug was actually approved for. Not B-tier because the specific use case the community buys it for is not the use case the evidence supports. Not D-tier because the pharmacology is real, the tanning effect is consistent and biologically plausible, and the drug itself has genuine regulatory standing. It also sits below melanotan ii, which holds no approval of its own: the grade follows the cosmetic tanning use, where melanotan ii carries the deeper grey-market record and the validation of spinning off an approved drug (PT-141), while melanotan i's real approval is for a rare-disease implant, not the vial people inject to tan.

the core tension

Melanotan I (afamelanotide) is in a genuinely unusual tier position: it has full FDA approval for erythropoietic protoporphyria (EPP), a rare genetic photosensitivity disorder where even brief sunlight exposure causes severe pain. The approved use is a subcutaneous implant administered by a dermatologist, tightly controlled. The grey-market use is something completely different, recreational tanning via self-injection, cycling on and off for cosmetic skin darkening. The drug is real. The rare-disease evidence is solid. The repeated cosmetic use case has no long-term safety data and raises specific dermatological concerns about nevus (mole) progression.

what it is

melanotan i is afamelanotide, a 13-amino-acid synthetic analog of alpha-msh designed at the university of arizona by victor hruby's group in the 1980s. norleucine at position 4 and d-phenylalanine at position 7 block enzymatic degradation, producing a stable mc1r-selective agonist. fda-approved as Scenesse in 2019 (eu approval 2014) for erythropoietic protoporphyria.

what it does

stimulates eumelanin production via mc1r activation, producing uv-independent skin darkening. for epp patients, that melanin boost lets them tolerate sunlight without porphyrin-mediated burning pain. for cosmetic users, it produces visible tanning over 2 to 6 weeks. selective for mc1r, so cleaner side effect profile than melanotan ii, less nausea, no sexual arousal effect, milder flushing.

origin

the melanotan program at arizona produced two molecules: melanotan i (the mc1r-selective afamelanotide) and melanotan ii (broader melanocortin activity). clinuvel pharmaceuticals took afamelanotide through phase 3 trials in epp, a genetic disorder affecting roughly 1 in 75,000 to 200,000 people, and won approval. the cuv039 and cuv029 registration studies showed clear pain-free sun-exposure benefit. a 2026 stability study mapped degradation pathways, exactly the boring chemistry work you see when a peptide is treated as a real drug product.

why researchers are interested

Scenesse genuinely changed lives for epp patients who were living in functional darkness. for the grey-market population, the tanning effect is reliable and the side effects are milder than mt-ii. the approved-indication safety record is reassuring even if it does not transfer to the way community users actually dose.

does it work

for epp, decisively yes. the orphan-drug evidence is rigorous and the approval is real. for cosmetic use, the mc1r-driven tanning effect is well documented, but the approved protocol is a 16mg controlled-release implant placed by a dermatologist every two months (~$49,000 per implant), not a daily subcutaneous shot. CUV105 phase 3 in vitiligo (Scenesse + NB-UVB phototherapy) finished enrollment May 2025; topline expected H2 2026. If positive, Scenesse becomes a real vitiligo drug, not just an EPP orphan. Long-term safety data on cycling healthy users does not exist. Dermatology case literature documents new mole formation and existing nevus changes. The drug is real. The drug that was studied is the implant, not the vial sold for cosmetic injection.

claims vs the data

• approved for erythropoietic protoporphyria (EPP) — supported — FDA-approved 2019, EU-approved 2014. Multiple Phase 3 trials (CUV039, CUV029, CUV010) supporting efficacy. Genuine rare-disease drug with real clinical evidence.
• increases skin melanin production — supported — Core established pharmacology. α-MSH agonists at MC1R stimulate melanogenesis. Dose-dependent darkening of skin is documented in both clinical trials and community use.
• safer than melanotan II for tanning — partially true — Melanotan I is more selective for MC1R (melanogenesis) versus MT-II's broader melanocortin activity (MC1R + MC3R + MC4R + MC5R). Fewer acute side effects, less nausea, no sexual arousal side effect, milder flushing. Long-term safety difference is not well-characterized in repeated cosmetic use.
• safe for repeated cosmetic tanning cycles — unverified — The approved Scenesse protocol is controlled dermatologist-administered implants with monitoring. Self-injection protocols cycling over years have no specific long-term safety data. Dermatologists have raised concerns about potential effects on existing nevi and melanocytic lesion monitoring.
• prevents skin cancer via UV-independent melanin — weak — Theoretical benefit sometimes claimed in tanning-community discussions. The protective effect of endogenously stimulated melanin against UV damage has some basis, but a meaningful skin-cancer protection claim requires clinical trial evidence that does not exist for repeated cosmetic melanotan use.
• causes new mole formation — partially true — Multiple case reports and dermatology observations of new nevi, darkening of existing nevi, and dysplastic changes in melanotan users. Not consistently quantified, but enough pattern to be a genuine clinical concern rather than a theoretical one.

key facts

• molecular formula: C78H111N21O19
• molecular weight: 1646.8 Da
• amino acids: 13
• half-life: approximately 30 minutes plasma half-life for the free peptide; the approved Scenesse formulation is a controlled-release subcutaneous implant providing roughly 2 months of sustained effect per implant
• type: synthetic α-MSH analog (tridecapeptide)
• CAS: 75921-69-6
• 2019 FDA approval year (Scenesse for EPP)
• 2014 EU approval year
• MC1R primary receptor selectivity
• <1:10,000 EPP prevalence, extremely rare disease

frequently asked questions

What is Melanotan I?

Melanotan I is afamelanotide, a synthetic 13-amino-acid analog of alpha-MSH (melanocyte stimulating hormone). Designed at the University of Arizona in the 1980s. FDA-approved as Scenesse in 2019 for erythropoietic protoporphyria, a rare photosensitivity disorder.

What does Melanotan I do?

MT-I stimulates melanin production via MC1R activation, providing sun protection through increased pigmentation. Approved Scenesse use treats EPP patients who cannot tolerate sunlight. Community use targets cosmetic tanning without UV exposure. MT-I has a cleaner side effect profile than MT-II, with less pronounced sexual and cardiovascular effects.

How is Melanotan I typically administered?

Approved Scenesse is a 16mg subcutaneous controlled-release implant placed under dermatologist supervision every 2 months for EPP patients. Grey-market cosmetic use is self-administered subcutaneous injection at frequencies reported as daily to every-other-day. The two patterns differ sharply in oversight and monitoring.

What are the side effects of Melanotan I?

Common: nausea (especially initial doses), facial flushing, darkening of existing moles and freckles, occasional new nevus formation. Less pronounced sexual and cardiovascular effects than MT-II. Long-term safety in healthy cosmetic users is not well-established.

Is Melanotan I FDA approved?

Yes, but narrowly. Afamelanotide was FDA-approved as Scenesse in October 2019 specifically for erythropoietic protoporphyria. EU approval 2014. Not approved for cosmetic tanning. Australian and other regulators have warned against grey-market cosmetic use.

How much does Melanotan I cost?

Branded Scenesse: approximately $49,000 per 16mg implant at orphan-drug pricing for EPP patients. Grey-market melanotan I sold for cosmetic use is inexpensive on the research-chemical market.

related peptides

• melanotan-ii — A-tier companion compound with broader melanocortin activity
• pt-141 — other melanocortin-family approved peptide (MC4R-preferring)
• ghk-cu — other skin-focused peptide with much stronger cosmetic evidence

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.